Japan · Delayed Price · Currency is JPY Stella Pharma Statistics
Total Valuation
Stella Pharma has a market cap or net worth of JPY 14.89 billion. The enterprise value is 11.98 billion.
| Market Cap | 14.89B |
| Enterprise Value | 11.98B |
Important Dates
The next estimated earnings date is Friday, November 6, 2026.
| Earnings Date | Nov 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Stella Pharma has 37.03 million shares outstanding. The number of shares has increased by 0.80% in one year.
| Current Share Class | 37.03M |
| Shares Outstanding | 37.03M |
| Shares Change (YoY) | +0.80% |
| Shares Change (QoQ) | +2.74% |
| Owned by Insiders (%) | 4.05% |
| Owned by Institutions (%) | 3.45% |
| Float | 22.69M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 46.09 |
| PB Ratio | 4.63 |
| P/TBV Ratio | 4.69 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 37.10 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 21.89, with a Debt / Equity ratio of 0.28.
| Current Ratio | 21.89 |
| Quick Ratio | 16.26 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.60 |
| Interest Coverage | -93.56 |
Financial Efficiency
Return on equity (ROE) is -27.19% and return on invested capital (ROIC) is -13.34%.
| Return on Equity (ROE) | -27.19% |
| Return on Assets (ROA) | -10.07% |
| Return on Invested Capital (ROIC) | -13.34% |
| Return on Capital Employed (ROCE) | -16.34% |
| Weighted Average Cost of Capital (WACC) | 5.56% |
| Revenue Per Employee | 6.87M |
| Profits Per Employee | -18.13M |
| Employee Count | 47 |
| Asset Turnover | 0.06 |
| Inventory Turnover | 0.04 |
Taxes
In the past 12 months, Stella Pharma has paid 2.00 million in taxes.
| Income Tax | 2.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +13.54% in the last 52 weeks. The beta is 0.29, so Stella Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.29 |
| 52-Week Price Change | +13.54% |
| 50-Day Moving Average | 339.76 |
| 200-Day Moving Average | 385.86 |
| Relative Strength Index (RSI) | 71.37 |
| Average Volume (20 Days) | 327,435 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Stella Pharma had revenue of JPY 323.00 million and -852.00 million in losses. Loss per share was -24.87.
| Revenue | 323.00M |
| Gross Profit | 279.00M |
| Operating Income | -842.00M |
| Pretax Income | -850.00M |
| Net Income | -852.00M |
| EBITDA | -815.50M |
| EBIT | -842.00M |
| Loss Per Share | -24.87 |
Balance Sheet
The company has 3.80 billion in cash and 898.00 million in debt, with a net cash position of 2.90 billion or 78.39 per share.
| Cash & Cash Equivalents | 3.80B |
| Total Debt | 898.00M |
| Net Cash | 2.90B |
| Net Cash Per Share | 78.39 |
| Equity (Book Value) | 3.22B |
| Book Value Per Share | 92.04 |
| Working Capital | 5.01B |
Cash Flow
In the last 12 months, operating cash flow was -334.00 million and capital expenditures -11.00 million, giving a free cash flow of -345.00 million.
| Operating Cash Flow | -334.00M |
| Capital Expenditures | -11.00M |
| Depreciation & Amortization | 26.50M |
| Net Borrowing | -19.00M |
| Free Cash Flow | -345.00M |
| FCF Per Share | -9.32 |
Margins
Gross margin is 86.38%, with operating and profit margins of -260.68% and -263.78%.
| Gross Margin | 86.38% |
| Operating Margin | -260.68% |
| Pretax Margin | -263.16% |
| Profit Margin | -263.78% |
| EBITDA Margin | -252.48% |
| EBIT Margin | -260.68% |
| FCF Margin | n/a |
Dividends & Yields
Stella Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.80% |
| Shareholder Yield | -0.80% |
| Earnings Yield | -5.72% |
| FCF Yield | -2.32% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Stella Pharma has an Altman Z-Score of 4.09 and a Piotroski F-Score of 2.
| Altman Z-Score | 4.09 |
| Piotroski F-Score | 2 |